[go: up one dir, main page]

WO2008149971A1 - 脳動脈瘤の治療または予防薬 - Google Patents

脳動脈瘤の治療または予防薬 Download PDF

Info

Publication number
WO2008149971A1
WO2008149971A1 PCT/JP2008/060434 JP2008060434W WO2008149971A1 WO 2008149971 A1 WO2008149971 A1 WO 2008149971A1 JP 2008060434 W JP2008060434 W JP 2008060434W WO 2008149971 A1 WO2008149971 A1 WO 2008149971A1
Authority
WO
WIPO (PCT)
Prior art keywords
cerebral aneurysm
therapeutic
prophylactic agent
protease inhibitor
cysteine protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/060434
Other languages
English (en)
French (fr)
Inventor
Nobuo Hashimoto
Hiroharu Kataoka
Tomohiro Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Kyoto University NUC
Original Assignee
Nippon Chemiphar Co Ltd
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd, Kyoto University NUC filed Critical Nippon Chemiphar Co Ltd
Priority to EP08765247A priority Critical patent/EP2168600A1/en
Priority to CN2008801025259A priority patent/CN101970007A/zh
Priority to US12/663,309 priority patent/US20110092484A1/en
Priority to JP2009517905A priority patent/JPWO2008149971A1/ja
Publication of WO2008149971A1 publication Critical patent/WO2008149971A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

【課題】脳動脈瘤の治療および予防に有効な医薬を提供する。 【解決手段】システインプロテアーゼ阻害剤を有効成分として含む脳動脈瘤の治療薬または予防薬を提供する。システインプロテアーゼ阻害剤として、エポキシコハク酸アミド誘導体またはその塩が好ましい。
PCT/JP2008/060434 2007-06-08 2008-06-06 脳動脈瘤の治療または予防薬 Ceased WO2008149971A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08765247A EP2168600A1 (en) 2007-06-08 2008-06-06 Therapeutic or prophylactic agent for cerebral aneurysm
CN2008801025259A CN101970007A (zh) 2007-06-08 2008-06-06 脑动脉瘤的治疗或预防药
US12/663,309 US20110092484A1 (en) 2007-06-08 2008-06-06 Therapeutic or prophylactic agent for cerebral aneurysm
JP2009517905A JPWO2008149971A1 (ja) 2007-06-08 2008-06-06 脳動脈瘤の治療または予防薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-152910 2007-06-08
JP2007152910 2007-06-08

Publications (1)

Publication Number Publication Date
WO2008149971A1 true WO2008149971A1 (ja) 2008-12-11

Family

ID=40093775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/060434 Ceased WO2008149971A1 (ja) 2007-06-08 2008-06-06 脳動脈瘤の治療または予防薬

Country Status (6)

Country Link
US (1) US20110092484A1 (ja)
EP (1) EP2168600A1 (ja)
JP (1) JPWO2008149971A1 (ja)
KR (1) KR20100023948A (ja)
CN (1) CN101970007A (ja)
WO (1) WO2008149971A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231024A (en) 1975-09-03 1977-03-09 Taisho Pharmaceut Co Ltd Process for preparation of epoxysuccinic acid esters
JPS6155509B2 (ja) 1978-09-30 1986-11-28 Taisho Pharma Co Ltd
JPH0841043A (ja) 1994-07-29 1996-02-13 Taisho Pharmaceut Co Ltd エポキシコハク酸誘導体
JPH08104684A (ja) 1994-05-31 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸関連化合物
WO1996030354A1 (en) 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Epoxysuccinic acid derivatives
WO1997021694A1 (en) 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
WO1998047887A1 (en) 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
WO1999011640A1 (en) 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
WO2001058886A1 (en) 2000-02-10 2001-08-16 Novartis Ag Dipeptide nitrile cathepsin k inhibitors
WO2001070232A1 (en) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Protease inhibitors
JP2002529422A (ja) * 1998-11-12 2002-09-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 虚血により傷害を受けた組織の処置法
JP2003519125A (ja) 1999-12-24 2003-06-17 エフ．ホフマン−ラ ロシュ アーゲー カテプシンｋ阻害剤としてのニトリル誘導体
WO2003053331A2 (en) 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
WO2003075836A2 (en) 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2003091202A1 (en) 2002-04-25 2003-11-06 Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
WO2005000800A1 (en) 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
WO2005066180A1 (en) 2004-01-08 2005-07-21 Medivir Ab Cysteine protease inhibitors
WO2007009715A1 (en) 2005-07-18 2007-01-25 Novartis Ag 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
WO2007025774A2 (en) 2005-09-02 2007-03-08 Glaxo Group Limited Cysteine protease inhibitors

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5231024A (en) 1975-09-03 1977-03-09 Taisho Pharmaceut Co Ltd Process for preparation of epoxysuccinic acid esters
JPS6155509B2 (ja) 1978-09-30 1986-11-28 Taisho Pharma Co Ltd
JPH08104684A (ja) 1994-05-31 1996-04-23 Takeda Chem Ind Ltd エポキシコハク酸関連化合物
JPH0841043A (ja) 1994-07-29 1996-02-13 Taisho Pharmaceut Co Ltd エポキシコハク酸誘導体
WO1996030354A1 (en) 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Epoxysuccinic acid derivatives
WO1997021694A1 (en) 1995-12-12 1997-06-19 Taiho Pharmaceutical Co., Ltd. Epoxysuccinamide derivatives or salts thereof, and drugs containing the same
WO1998047887A1 (en) 1997-04-18 1998-10-29 Taiho Pharmaceutical Co., Ltd. Novel epoxysuccinamide derivatives or salts thereof
WO1999011640A1 (en) 1997-09-04 1999-03-11 Nippon Chemiphar Co., Ltd. Epoxysuccinamide derivatives
JP2002529422A (ja) * 1998-11-12 2002-09-10 リサーチ コーポレイション テクノロジーズ，インコーポレイテッド 虚血により傷害を受けた組織の処置法
JP2003519125A (ja) 1999-12-24 2003-06-17 エフ．ホフマン−ラ ロシュ アーゲー カテプシンｋ阻害剤としてのニトリル誘導体
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
WO2001058886A1 (en) 2000-02-10 2001-08-16 Novartis Ag Dipeptide nitrile cathepsin k inhibitors
WO2001070232A1 (en) 2000-03-21 2001-09-27 Smithkline Beecham Corporation Protease inhibitors
WO2003053331A2 (en) 2000-11-22 2003-07-03 Smithkline Beecham Corporation Protease inhibitors
WO2003075836A2 (en) 2002-03-05 2003-09-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
WO2003091202A1 (en) 2002-04-25 2003-11-06 Ono Pharmaceutical Co., Ltd. Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient
WO2004108661A1 (en) 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
WO2005000800A1 (en) 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
WO2005066180A1 (en) 2004-01-08 2005-07-21 Medivir Ab Cysteine protease inhibitors
WO2007009715A1 (en) 2005-07-18 2007-01-25 Novartis Ag 2-cyano-pyrimidines and -triazines as cysteine protease inhibitors
WO2007025774A2 (en) 2005-09-02 2007-03-08 Glaxo Group Limited Cysteine protease inhibitors

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"ABSTRACT, RESULTS, GENE EXPRESSION ANALYSIS", J. VASC. RES., vol. 45, 2008, pages 343 - 349, XP008127254 *
AOKI TOMOHIRO ET AL.: "Macrophage-derived matrix metalloprotease-2 and -9 promote the progression of cerebral aneurysms in rats", STROKE, vol. 38, 2007, pages 162 - 169
C.S. LI ET AL., BIOORG., MED. CHEM. LETT., vol. 16, 2006, pages 1985 - 1989
J. ROBICHAUD ET AL., J. MED. CHEM., vol. 46, 2003, pages 3709 - 3727
N. KATUMUMA ET AL., FEBS LETT., vol. 458, 1999, pages 6 - 10
NAGATA I; HANDA H; HASHIMOTO N; HAZAMA F.: "Experimentally induced cerebral aneurysms in rats: Part VI. Hypertension", SURG NEUROL., vol. 14, 1980, pages 477 - 479
P.D. GREENSPAN ET AL., BIOORG., MED. CHEM. LETT., vol. 13, 2003, pages 4121 - 4124
R.W. MARQUIS ET AL., J. MED. CHEM., vol. 44, 2001, pages 1380 - 1395
STROKE, vol. 32, 2001, pages 1036 - 1042, XP008127227 *
T. OTSUKA ET AL., J. ANTIBIOT., vol. 52, 1999, pages 536 - 541
T. YASUMA ET AL., J. MED. CHEM., vol. 41, 1998, pages 4301 - 4308

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014175287A1 (ja) 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
US9629834B2 (en) 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same

Also Published As

Publication number Publication date
EP2168600A1 (en) 2010-03-31
US20110092484A1 (en) 2011-04-21
CN101970007A (zh) 2011-02-09
KR20100023948A (ko) 2010-03-04
JPWO2008149971A1 (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2008088030A1 (ja) 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
WO2007087431A3 (en) Sublingual fentanyl spray
PL1814534T3 (pl) Pochodne kwasu 5-aminolewulinowego do leczenia trądziku
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2011091213A3 (en) Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2009017837A3 (en) Sublingual fentanyl spray
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
HK1211475A1 (en) Combination therapy
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease
WO2008153318A3 (en) Transglutaminase inhibitor comprising chlorogenic acid and a method for producing thereof
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease
WO2007130419A3 (en) Histone deacetylase inhibitors for the treatment of neurodegeneration
WO2009150257A3 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EP2392335A3 (en) Use of 24-norUDCA
WO2008149971A1 (ja) 脳動脈瘤の治療または予防薬
WO2010013925A3 (en) Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
WO2008099906A1 (ja) 歯周病、及び外科手術による歯槽骨欠損の治療剤
TN2012000568A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
WO2007062862A3 (en) Use of calmodulin inhibitors for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880102525.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765247

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009517905

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12663309

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20107000072

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008765247

Country of ref document: EP